AstraZeneca (NASDAQ:AZN) announced an agreement to buy
Alexion Pharmaceuticals (NASDAQ:ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. Based on AstraZeneca s closing price on Friday, Alexion shareholders are in line to receive about $175 per share.
Regulatory hurdles that come with big international mergers are expected to keep this one from completing until the third quarter of 2021. Based on yesterday s closing prices for both stocks, though, AstraZeneca s offer represents a 45% premium.
Image source: Getty Images.
If regulators don t try to halt the deal, Alexion shareholders will own around 15% of a much larger AstraZeneca by this time next year. Alexion shareholders are in line to receive $60 in cash plus 2.1243 of AstraZeneca s American depository shares (ADS).